{"filing":{"accession_number":"0001193125-26-333834","cik":"0001815442","ticker":"KYMR","company_name":"Kymera Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"kymr-20260805.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526333834/kymr-20260805.htm"},"events":[{"id":24480,"run_id":22183,"accession_number":"0001193125-26-333834","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Kymera Therapeutics disclosed its financial results for the quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly financial metrics (collaboration revenues of $65.0 million, R\u0026D expenses of $119.5 million, net loss of $61.2 million) and cash position ($1.5 billion), along with business updates on clinical pipeline progress. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and operational progress.","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":25043,"accession_number":"0001193125-26-333834","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Kymera Therapeutics disclosed its financial results for the quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly financial metrics (collaboration revenues of $65.0 million, R\u0026D expenses of $119.5 million, net loss of $61.2 million) and cash position ($1.5 billion), along with business updates on clinical pipeline progress. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:39:19.296051+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":25043,"accession_number":"0001193125-26-333834","item_number":"2.02","item_title":"Results of Operations and Financial Condition","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Kymera Therapeutics disclosed its financial results for the quarter ended June 30, 2026, via a press release furnished as Exhibit 99.1. The disclosure includes quarterly financial metrics (collaboration revenues of $65.0 million, R\u0026D expenses of $119.5 million, net loss of $61.2 million) and cash position ($1.5 billion), along with business updates on clinical pipeline progress. This is a standard quarterly earnings release under Item 2.02, material to investors assessing the company's financial condition and operational progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:39:19.296051+00:00","company_name":"Kymera Therapeutics, Inc.","ticker":"KYMR","filing_date":"2026-08-05"}]}